TIME EVENT
Limited to 30 participants, First Come, First Served Basis
8:00 AM
SESSION I. STATE OF THE ART IN PROSTATE CANCER CARE: CURRENT AND POTENTIAL IMPACT OF PRECISION DIAGNOSTICS ON PRECISION CARE
Moderators:
Adam Kibel, MD, Professor of Surgery and Chief of Urology, Brigham and Women’s Hospital and Dana Farber Cancer Institute, Harvard Medical School
Howard Scher, MD, Chief, Genitourinary Oncology Service, Sidney Kimmel Center for Urologic and Prostate Cancers, Memorial Sloan Kettering; D. Wayne Calloway Chair in Urologic Oncology and Professor of Medicine, Weill Cornell Medical College
8:05 AM
Introduction and Statement of Purpose:
Faina Shtern, MD, President & CEO, AdMeTech Foundation
8:20 AM
Featured Clinical Reviews: Current and Potential Impact of Precision Diagnostics on Clinical Practice
8:20 AM
Urology Perspective on Low-Risk Disease: Adam Kibel, MD
8:35 AM
Q & A
8:40 AM
Radiation Oncology Perspective on High-Risk Disease: Alan Pollack, MD, PhD, Professor and Chairman of Radiation Oncology, University of Miami Miller School of Medicine
8:55 AM
Q & A
9:00 AM
Radiology Perspective
9:00 AM
Anatomic Imaging: Clare Tempany, MD, Professor and Ferenc Jolesz Chair for Radiology Research, Brigham and Women’s Hospital, Harvard Medical School
9:15 AM
Molecular Imaging: Steven Larson, MD, Professor and Chief of Nuclear Medicine, Memorial Sloan Kettering Cancer Center
9:30 AM
Q & A
9:35 AM
Pathology Perspective
9:35 AM
Anatomic Pathology: Thomas Wheeler, MD, Chairman and Professor of Pathology, Baylor College of Medicine
9:50 AM
Molecular Pathology: Angelo DeMarzo, MD, PhD, Associate Professor of Pathology, Urology, Oncology, Johns Hopkins University School of Medicine
10:05 AM
Q & A
10:10 AM
Medical Oncology Perspective on Advanced Disease: Howard Scher, MD, Chief, Genitourinary Oncology Service, Sidney Kimmel Center for Urologic and Prostate Cancers, Memorial Sloan Kettering; D. Wayne Calloway Chair in Urologic Oncology and Professor of Medicine, Weill Cornell Medical College
10:25 AM
Q & A
10:25 AM – 10:45 AM
Clinical Reviews Panel Discussion: Moderators, & Speakers
10:45 AM – 11:00 AM
Coffee Break
11:00 AM
SESSION II. SCREENING IN GENERAL (ASYMPTOMATIC) POPULATION:
STATE OF THE ART AND VISION FOR THE FUTURE
Moderators:
Laurence Klotz, MD, Professor of Surgery, University of Toronto; Chief of Urology, Sunnybrook Health Services
Anthony Zietman, MD, Jenot W. and William U. Shipley Professor of Radiation Oncology, Department of Radiation Oncology, Harvard Medical School
11:05 AM
Current and Future Role of PSA Screening
Selection of Patients for Screening
Laurence Klotz, MD
11:20 AM
Regional Central/Western Massachusetts Perspective and Health Disparities:
Mitchell Sokoloff, MD, Professor and Chair of Urology, University of Massachusetts School of Medicine
11:35 PM
Q & A
11:40 AM
Increasing Benefits and Reducing Risks of Screening:
Defining the Need for Improved Diagnostic Tools
11:40 AM
National Comprehensive Cancer Center Guidelines, Baseline PSA and phi
Sigrid Carlsson, MD, PHD, MPH, Assistant Attending Epidemiologist, Department of Surgery (Urology Service), Memorial Sloan Kettering Cancer Center and Associate Professor of Experimental Urology, Sahlgrenska Academy, Gothenburg University, Sweden
11:55 PM
Risk Stratification and Patient Outcomes
Jennifer Rider, ScD, MPH, Assistant Professor, Department of Epidemiology, Boston University School of Public Health
12:10 PM
Q & A
12:15 PM
Screening Panel Discussion – Moderators, Speakers, Mark Katz, MD, Assistant Professor of Urology, Boston University School of Medicine
12:45 PM to 1:45 PM
Lunch
1:45 PM
SESSION III: POPULATION-BASED REVIEW OF IN VITRO DIAGNOSTICS: NOVEL BIOMARKERS, MOLECULAR AND GENOMIC TOOLS
Session IIIA. Current and Emerging Role of In Vitro Diagnostic Tools in a General Population of Asymptomatic Men and in a Population of Men with Abnormal Screening Results
Moderators: Angelo DeMarzo, MD, PhD and Laurence Klotz, MD
1:50 PM
Urology Perspective
1:50 PM
Pre-Diagnosis Overview: Matthew Cooperberg, MD, MPH, Associate Professor, Department of Urology and Epidemiology & Biostatistics, Helen Diller Family Chair in Urology, University of California, San Francisco
2:05 PM
Clinical Evaluation of Novel Screening Tools: Stephen Zappala, MD, Assistant Clinical Professor of Urology, Tufts University School of Medicine
2:20 PM
Q & A
2:25 PM
Pathology Perspective:
Massimo Loda, MD, Professor of Pathology and Director, Center for Molecular Oncologic Pathology, Dana Farber Harvard Cancer Center, Harvard Medical School
2:40 PM
Q & A
2:45 PM
Clinical Discussion Facilitators:
Adam Kibel, MD, Howard Scher, MD, and Anthony Zietman, MD
2:55 PM
Session IIIA Panel Discussion: Moderators, Speakers, and Facilitators
3:30 PM
Coffee Break
3:50 PM
Session IIIB: Current and Emerging Role of In Vitro Diagnostics in a Population of Men With Proven Prostate Cancer
Moderators:
Howard Scher, MD and Massimo Loda, MD
3:55 PM
Pathology Perspective
3:55PM
General Overview: Tissue-Based Diagnosis
Angelo DeMarzo, MD, PhD
4:10 PM
Tissue-Cell Based Multiplex / Morphometric Biomarker Assays/Fluid Biopsies
Michael Donovan, MD, PhD, Professor of Pathology, Mount Sinai Medical Center
4:25 PM
Q & A
4:30 PM
Radiation Oncology Perspective: Gene Expression Signatures and Biomarker Model For Radiotherapy Patients
Alan Pollack, MD, PhD
4:45 PM
Q & A
4:50 PM
Session IIIB Panel Discussion: Moderators, Speakers, Matthew Cooperberg, MD, MPH, Laurence Klotz, MD
5:20 PM
SESSION IV: INTERFACE BETWEEN IN VITRO DIAGNOSTICS AND IN VIVO IMAGING
Moderators:
Jason Efstathiou, M.D., D.Phil., Associate Professor, Harvard Medical School & Director, Genitourinary Division, Massachusetts General Hospital; and Steven Larson, MD
5:25 PM
Integration of Biomarkers and mpMRI for Improved Risk Assessment
Sanoj Punnen, MD, Urologic Oncologist and Assistant Professor, University of Miami Miller School of Medicine
5:40 PM
Q & A
5:45 PM
Transition from In Vitro to In Vivo Imageable Targets in Nuclear Medicine/PET
Umar Mahmood, MD, PHD, Professor of Radiology, Harvard Medical School and Director, Division of Precision Medicine, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital
6:00 PM
Q & A
6:05 PM
Clinical Discussion Facilitators/Comments:
Angelo DeMarzo, MD, PhD, Massimo Loda, MD, Allan Pollack, MD, PhD, and Howard Scher, MD
6:15 PM – 6:30 PM
Panel, Part I Discussion: Moderators, Facilitators, Speakers
7:00 PM
DINNER RECEPTION, POSTERS PRESENTATIONS & SESSION ON INDUSTRIAL INNOVATION
Moderators:
Laurence Klotz, MD and Alan Pollack, MD, PhD
In Vitro Diagnostics
Overview: Ron Mazumber, Ph.D., Global Head, Research and Product Development, Janssen Diagnostics, Johnson and Johnson
Screening and Selection of Patients for Biopsy: David Okrongly, Ph.D., President, OPKO Diagnostics
Tissue-Based Genetic Signatures and Selection of Patients for Treatment:
Brian Liu, PhD., Medical Science Liaison-Urology, Myriad Genetics
Genomic Health (TBA)
Post-Treatment Evaluation and Treatment Planning: Jennifer Jordan, PhD, Clinical Genomic Liaison, GenomeDx Biosciences
In Vivo Imaging
Molecular Imaging for Improved Tissue Characterization: Jonathan Allis, D.Phil., CEO, Blue Earth Diagnostics
mpMRI and Ultrasound for Improved Screening and Diagnosis
Randall Jones, D.E. (PhD, MBA), President & CEO, ScanMed
Antoine Leroy, Ph.D., President and CEO, Koelis
Rajesh Venkataraman, Ph.D., Research and Development Manager, Eigen/Hitachi
Integration of In Vivo and In Vitro Diagnostics
Richard Frank, MD, Ph.D., Chief Medical Officer, and Heinrich von Busch, Global Product Manager, MR Oncology; Siemens Healthcare
John Feller, MD, Medical Director and Founder, Desert Medical Imaging
8:00 AM
SESSION V, IN VIVO IMAGING TOOLS
Session V, Part I: Current and Emerging Role of In Vivo Imaging in a General Population of Asymptomatic Men, and in a Population of Men with Abnormal Screening Results
Moderators: Fergus Coakley, MD, Professor and Chairman of Radiology, School of Medicine, Oregon Health and Science University; Angelo DeMarzo, MD, PhD; and Howard Scher, MD
8:05 AM
Multi-Parametric MRI (mpMRI)
8:05 AM
PI-RADS Standardization: Impact on Patient Selection for Biopsies, Tissue Sampling and Assessment of Aggressiveness
History and Clinical Adaptation:
Jeffrey Weinreb, MD, Professor and Vice Chair for Strategic Planning and Innovation, Department of Diagnostic Radiology and Biomedical Imaging, Yale School of Medicine
Role in Screening and Detecting Clinically Significant Prostate Cancer:
Jelle Barentsz, MD, PhD, Chair and Professor of Radiology Prostate MR Center of Excellence, Nijmegen Medical Center, Radboud University, The Netherlands
8:35 AM
Q & A
8:40 AM
Clinical Role of MRI and Multi-Modality Image Fusion in Screening and Diagnostic Assessment of Men with Abnormal Screening:
Baris Turkbey, MD, Staff Clinician/Radiologist, National Cancer Institute
8:55 AM
Q & A
9:00 AM
Ultrasound Update for Detection of Prostate Cancer:
Ethan Halpern, MD, Vice Chair for Research and Co-Director, Jefferson Prostate Diagnostic Center, and Professor of Radiology, Thomas Jefferson University
9:15 AM
Q & A
9:20 AM
Clinical Discussion Facilitators:
Laurence Klotz, MD and Anwar Padhani, MD, Head of Imaging Research, Mount Vernon Cancer Center, United Kingdom
9:25 AM to 9:55 AM
Session V, Part I Panel Discussion: Moderators, Facilitators, Speakers, and
Masoom Haider, MD, Professor of Radiology, University of Toronto, Head of Abdominal MRI, Sunnybrook Health Services Center, Canada;
Daniel Margolis, MD, Co-Director of Prostate MRI and Assistant Professor of Radiology, UCLA;
Sadhna Verma, MD, Associate Professor of Radiology, University of Cincinnati College of Medicine
9:55 AM to 10:10 AM
Coffee Break
10:10 AM
Session V, Part II. Imaging Tools in a Population of Men With Proven Prostate Cancer
10:10 AM
Multi-Parametric (mp) MRI
Moderators: Laurence Klotz, MD, and Clare Tempany, MD
10:15 AM
mpMRI in the Risk Assessment Proven Cancer
10:15 AM
Overview: Anwar Padhani, MD
10:30 AM
Low Risk Prostate Cancer and Selection of Patients for Active Surveillance vs. Treatment
Masoom Haider, MD
10:45 AM
Q & A
10:50 AM
mpMRI and Cost-Effectiveness of Patient Care
10:50 AM
Impact of Improved Patient Selection for Biopsies: Jelle Barentsz, MD
11:00 AM
Impact of Improved Patient Selection for Treatment: Neil Martin, MD, MPH, Assistant Professor of Radiation Oncology, Dana Farber/ Brigham and Women’s Cancer Center, Harvard Medical School
11:10 AM
Clinical Discussion Facilitators:
Adam Feldman, MD, MPH, Assistant Professor of Surgery and Director of Combined Harvard Urology Oncology Fellowship, Massachusetts General Hospital, Harvard Medical School; and Anwar Padhani, MD
11:20 AM
mpMRI Panel Discussion: Speakers, Moderators, Facilitators,
Amita Shukla-Dave, PHD, Director of Quantitative Imaging and Attending Physicist, Memorial Sloan Kettering Cancer Center;
Nicolas Bloch, MD, Chief of MRI and Associate Professor of Radiology, Boston University Medical Center; and
Mukesh Harisinghani, MD, Director of Abdominal MRI, Massachusetts General Hospital and Professor of Radiology, Harvard Medical School.
11:45 AM
Molecular Imaging: Nuclear Medicine/PET and Optical Imaging
Moderators: Angelo DeMarzo, MD, PhD, Steven Larson, MD and Allan Pollack, MD, PhD
11:55 AM
Overview: Wolfgang Weber, MD, Chief, Molecular Imaging and Therapy Service Department of Radiology, Memorial Sloan Kettering Cancer Center
12:10 PM
Q & A
12:15 PM
PSMA-Targeted Imaging: Martin Pomper, MD, PhD, Professor of Radiology (Nuclear Medicine and PET), Johns Hopkins University School of Medicine
12:30 PM
Q & A
12:35 PM
Amino Acid Imaging: David Schuster, MD, Associate Professor, Director, Division of Nuclear Medicine and Molecular Imaging, GRA Distinguished Cancer Scientist, Department of Radiology and Imaging Sciences, Emory University Hospital
12:50 PM
Q & A
12:55 PM to 1:20 PM
Molecular Imaging Panel Discussion: Moderators and Speakers
1:20 PM to 2:20 PM
Lunch
2:20 PM to 3:20 PM
Session VI: Multi-factorial, Multi-disciplinary, Multi-modality-Based Diagnostic Assessment for Selection of Patients for Screening, Biopsies and Treatment
Moderators: Adam Kibel, MD; Alan Pollack, MD, PhD; and Daniel Petrylak, MD, Professor of Medicine (Medical Oncology) and Urology; and Co-Director, Signal Transduction Research Program, Yale University Cancer Center
2:20 PM – 2:35 PM
Phenotypic Diagnostics in Living Cells: Interface with Genomics and In Vivo Imaging
David Albala, MD, Chief of Urology, Crouse Hospital in Syracuse, New York; and Medical Director for Associated Medical Professionals
2:35 PM to 3:20 PM
General Discussion: – Moderators, Facilitators and Speakers (All Sessions)
3:30PM – 3:45PM Coffee Break
3:45 PM to 4:30 PM
SESSION VI: PANEL ON EFFECTIVE MODELS FOR TRANSFER OF PROMISING
DIAGNOSTIC TOOLS FROM LABORATORIES TO CLINICS
Lynette Sholl, MD, Associate Pathologist, Brigham and Women’s Hospital, Assistant Professor of Pathology, Harvard Medical School
Christiane Kuhl, MD, Professor and Chair, Department of Radiology, University of Aachen, Germany
Martin Yaffe, PhD, Professor, Department of Medical Imaging and Biophysics, University of Toronto
4:30 PM to 5:30 PM
GENERAL DISCUSSION AND CONCLUSIONS: Executive Leadership Team
Faina Shtern, MD, Adam Kibel, MD, Clare Tempany, MD, Fergus Coakley, MD, Laurence Klotz, MD, Angelo DeMarzo, MD, PHD, Alan Pollack, MD, PHD, and Howard Scher, MD
5:30PM ADJOURN
